2,524
Views
2
CrossRef citations to date
0
Altmetric
Research Article

Streptococcus Pneumoniae septic arthritis in adults in Bristol and Bath, United Kingdom, 2006–2018: a 13-year retrospective observational cohort study

ORCID Icon, ORCID Icon, ORCID Icon, , ORCID Icon, ORCID Icon, ORCID Icon & show all
Pages 1369-1377 | Received 03 May 2021, Accepted 16 Jun 2021, Published online: 05 Jul 2021

References

  • Weston VC, Jones AC, Bradbury N, et al. Clinical features and outcome of septic arthritis in a single UK Health district 1982–1991. Ann Rheum Dis. 1999;58(4):214.
  • Geirsson AJ, Statkevicius S, Víkingsson A. Septic arthritis in Iceland 1990-2002: increasing incidence due to iatrogenic infections. Ann Rheum Dis. 2008;67(5):638–643.
  • Abram SGF, Alvand A, Judge A, et al. Mortality and adverse joint outcomes following septic arthritis of the native knee: a longitudinal cohort study of patients receiving arthroscopic washout. Lancet Infect Dis. 2020;20(3):341–349.
  • Gupta MN, Sturrock RD, Field M. Prospective comparative study of patients with culture proven and high suspicion of adult onset septic arthritis. Ann Rheum Dis. 2003;62(4):327.
  • Mathews CJ, Weston VC, Jones A, et al. Bacterial septic arthritis in adults. The Lancet. 2010 2010;375(9717):846–855.
  • Shirtliff ME, Mader JT. Acute septic arthritis. Clin Microbiol Rev. 2002;15(4):527–544.
  • Ispahani P, Weston VC, Turner DPJ, et al. Septic arthritis due to Streptococcus pneumoniae in nottingham, United Kingdom, 1985–1998. Clin Infect Dis. 1999;29(6):1450–1454.
  • Ross JJ, Saltzman CL, Carling P, et al. Pneumococcal septic arthritis: review of 190 cases. Clin Infect Dis. 2003;36(3):319–327.
  • Salisbury D, Ramsay M, Noakes K. Immunisation against infectious disease. In: Salisbury D, Ramsay M, Noakes K, editors. The Green book. Vol. Norwick 2013. The Stationary Office; 2016. p. 295–313.
  • Ganaie F, Maruhn K, Li C, et al.. structural, genetic, and serological elucidation of Streptococcus pneumoniae serogroup 24 serotypes: discovery of a new serotype, 24C, with a variable capsule structure. J Clin Microbiol. 2021;59(7):e0054021. doi:https://doi.org/10.1128/JCM.00540-21
  • Miller E, Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11(10):760–768.
  • Waight PA, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15(5):535–543.
  • Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. Lancet Infect Dis. 2018;18(4):441–451.
  • Houseman C, Hughes GJ, Chapman KE, et al. Increased invasive pneumococcal disease, North east England, UK. Emerg Infect Dis. 2017;23(1):122–126.
  • Steens A, Bergsaker MAR, Aaberge IS, et al. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine. 2013;31(52):6232–6238.
  • Jayasinghe S, Menzies R, Chiu C, et al. Long-term impact of a “3 + 0” schedule for 7- and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in Australia, 2002-2014. Clin Infect Dis. 2017;64(2):175–183.
  • Regev-Yochay G, Katzir M, Strahilevitz J, et al. The herd effects of infant PCV7/PCV13 sequential implementation on adult invasive pneumococcal disease, six years post implementation; a nationwide study in Israel. Vaccine. 2017;35(18):2449–2456.
  • Lepoutre A, Varon E, Georges S, et al. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012. Vaccine. 2015;33(2):359–366.
  • Amin-Chowdhury Z, Collins S, Sheppard C, et al. Characteristics of invasive pneumococcal disease caused by Emerging serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in England: A prospective observational cohort study, 2014–2018. Clin Infect Dis. 2020;71(8):e235–e243.
  • Amin-Chowdhury Z, Groves N, Sheppard CL, et al. Invasive pneumococcal disease due to 22F and 33F in England: A tail of two serotypes. Vaccine. 2021 Apr 1;39(14):1997–2004.
  • Database NHF. National Hip Fracture Database, Annual Report. 2016.
  • Dernoncourt A, El Samad Y, Schmidt J, et al. Case studies and literature review of pneumococcal septic arthritis in adults. Emerging Infectious Disease Journal. 2019;25(10):1824.
  • Marrie TJ, Tyrrell GJ, Majumdar SR, et al. Rates of, and risk factors for, septic arthritis in patients with invasive pneumococcal disease: prospective cohort study. BMC Infect Dis. 2017;17(1):680.
  • Belkhir L, Rodriguez-Villalobos H, Vandercam B, et al. Pneumococcal septic arthritis in adults: clinical analysis and review. Acta Clin Belg. 2014;69(1):40–46.
  • Morse A. Discharging older patients from hospital - National audit Office (NAO) report. London: Department of Health and Social Care; 2016.
  • de Morton NA, Keating JL, Jeffs K. Exercise for acutely hospitalised older medical patients. Cochrane Database Syst Rev. 2007;1:1465–1858.
  • Covinsky KE, Palmer RM, Fortinsky RH, et al. Loss of independence in activities of daily living in older adults hospitalized with medical illnesses: increased vulnerability with age. J Am Geriatr Soc. 2003;51(4):451–458.
  • Statistics OoN. Deaths involving MRSA: 2008 to 2012. Statistical Bulletin; August 2013.
  • Hyams C, Williams OM, Williams P. Urinary antigen testing for pneumococcal pneumonia: is there evidence to make its use uncommon in clinical practice? ERJ Open Res. 2020;6(1):00223–02019.